Oxidative stress and microvascular function in insulin-resistant states

Microcirculation and Insulin Resistance

Volumn , Issue , 2009, Pages 70-84

  Rosen P ^a   Rosen R ^b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860473919     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805057410901010070     Document Type: Chapter

References (119)

1. Brunner, H.; Cockcroft, J. R.; Deanfield, J.; Donald, A.; Ferrannini, E.; Halcox, J.; Kiowski, W.; Luscher, T. F.; Mancia, G.; Natali, A.; Oliver, J. J.; Pessina, A. C.; Rizzoni, D.; Rossi, G. P.; Salvetti, A.; Spieker, L. E.; Taddei, S.; Webb, D. J. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 23:233-246; 2005.
2. Rask-Madsen, C.; King, G. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 3:46-56; 2007.
3. Andersen, K.; Pedersen, B. K. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm Metab Res 40:635-639; 2008.
4. Jonk, A. M.; Houben, A. J.; de Jongh, R. T.; Serne, E. H.; Schaper, N. C.; Stehouwer, C. D. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology. (Bethesda.) 22:252-260; 2007.
5. Packer, L.; Rösen, P.; Tritschler, H.; King, G. L.; Azzi, A. Antioxidants in diabetes management.: New York Marcel Dekker; 2000.
6. Rosen, P.; Nawroth, P. P.; King, G.; Moller, W.; Tritschler, H. J.; Packer, L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 17:189-212; 2001.
7. Sies, E. Antioxidants in disease: mechanisms and therapy: London Academic Press; 1997.
8. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820; 2001.
9. Nishikawa, T.; Edelstein, D.; Brownlee, M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int. Suppl 77:S26-S30; 2000.
10. Baynes, J. W. Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412; 1991.
11. Consitt, L. A.; Bell, J. A.; Houmard, J. A. Intramuscular lipid metabolism, insulin action, and obesity. IUBMB. Life 61:47-55; 2009.
12. Karlsson, H. K.; Zierath, J. R. Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochem. Biophys. 48:103-113; 2007.
13. Gallagher, E. J.; LeRoith, D.; Karnieli, E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol. Metab Clin. North Am. 37:559-79, vii; 2008.
14. Yudkin, J. S. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 39:707-709; 2007.
15. Ziegler, D.; Sohr, C. G.; Nourooz-Zadeh, J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 27:2178-2183; 2004.
16. Stirban, A.; Rosen, P.; Tschoepe, D. Complications of type 1 diabetes: new molecular findings. Mt. Sinai J. Med. 75:328-351; 2008.
17. Wellen, K. E.; Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest 115:1111-1119; 2005.
18. Katagiri, H.; Yamada, T.; Oka, Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ. Res 101:27-39; 2007.
19. Facchini, F. S.; Hua, N.; Abbasi, F.; Reaven, G. M. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab 86:3574-3578; 2001.
20. Yip, J.; Facchini, F. S.; Reaven, G. M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab 83:2773-2776; 1998.
21. DeFronzo, RA. Pathogenesis of type 2 diabetes:metabolic and molecular implications for identifying diabetes genes. Diabetes Reviews 5, 177-269. 1997.
22. Reaven, G. Insulin resistance and its consequences: type 2 diabetes and coronary heart disease. In LeRoith, D.; Taylor, S.; Olefsky, J. eds. Diabetes mellitus: A fundamental and clinical text. Philadelphia: Lippicott Williams & Wilkins; 2000:604-615.
23. Natali, A.; Baldi, S.; Vittone, F.; Muscelli, E.; Casolaro, A.; Morgantini, C.; Palombo, C.; Ferrannini, E. Effects of glucose tolerance on the changes provoked by glucose ingestion in microvascular function. Diabetologia 51:862-871; 2008.
24. Ceriello, A.; Esposito, K.; Piconi, L.; Ihnat, M. A.; Thorpe, J. E.; Testa, R.; Boemi, M.; Giugliano, D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-1354; 2008.
25. Ceriello, A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1-7; 2005.
26. Frisbee, J. C. Obesity, insulin resistance, and microvessel density. Microcirculation. 14:289-298; 2007.
27. Knudson, J. D.; Dincer, U. D.; Bratz, I. N.; Sturek, M.; Dick, G. M.; Tune, J. D. Mechanisms of coronary dysfunction in obesity and insulin resistance. Microcirculation. 14:317-338; 2007.
28. Rebolledo, OR, Marra, CA, Raschia, A, Rodriguez, S, and Gagliardino, JJ. Abdominal adipose tissue: early metabolic dysfunction associated to insulin resistance and oxidative stress induced by an unbalanced diet. Horm Metab Res 40, 794-800. 2008.
29. Ceriello, A.; Assaloni, R.; Da Ros, R.; Maier, A.; Piconi, L.; Quagliaro, L.; Esposito, K.; Giugliano, D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 111:2518-2524; 2005.
30. Ceriello, A.; Quagliaro, L.; Piconi, L.; Assaloni, R.; Da Ros, R.; Maier, A.; Esposito, K.; Giugliano, D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53:701-710; 2004.
31. Ceriello, A. Nitrotyrosine: new findings as a marker of postprandial oxidative stress. Int. J. Clin. Pract. Suppl 51-58; 2002.
32. Puddu, P.; Puddu, G. M.; Cravero, E.; Rosati, M.; Muscari, A. The molecular sources of reactive oxygen species in hypertension. Blood Press 17:70-77; 2008.
33. Holvoet, P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd. Belg. 70:193-219; 2008.
34. Lavie, L. Oxidative stress--a unifying paradigm in obstructive sleep apnea and comorbidities. Prog. Cardiovasc. Dis. 51:303-312; 2009.
35. Thomas, S. R.; Witting, P. K.; Drummond, G. R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox. Signal. 10:1713-1765; 2008.
36. Schulz, E.; Jansen, T.; Wenzel, P.; Daiber, A.; Munzel, T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid. Redox. Signal. 10:1115-1126; 2008.
37. Grossman, E. Does increased oxidative stress cause hypertension? Diabetes Care 31 Suppl 2:S185-S189; 2008.
38. Ceriello, A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 31 Suppl 2:S181-S184; 2008.
39. Halliwell, B. Antioxidants: the basics - what they are - how to evaluate them. In Sies, H. eds. Antioxidants in disease: mechanisms and therapy. London: Academic Press; 1997:3-20.
40. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H. Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; Sano, H.; Utsumi, H.; Nawata, H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939-1945; 2000.
41. Christ, M.; Bauersachs, J.; Liebetrau, C.; Heck, M.; Gunther, A.; Wehling, M. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 51:2648-2652; 2002.
42. Akbari, C. M.; Saouaf, R.; Barnhill, D. F.; Newman, P. A.; LoGerfo, F. W.; Veves, A. Endotheliumdependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J. Vasc. Surg. 28:687-694; 1998.
43. Du, X.; Stocklauser-Farber, K.; Rosen, P. Generation of reactive oxygen intermediates, activation of NFkappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic. Biol Med. 27:752-763; 1999.
44. Du, X. L.; Sui, G. Z.; Stockklauser-Farber, K.; Weiss, J.; Zink, S.; Schwippert, B.; Wu, Q. X.; Tschope, D.; Rosen, P. Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia 41:249-256; 1998.
45. Du, X.; Matsumura, T.; Edelstein, D.; Rossetti, L.; Zsengeller, Z.; Szabo, C.; Brownlee, M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest 112:1049-1057; 2003.
46. Ceriello, A.; Bortolotti, N.; Crescentini, A.; Motz, E.; Lizzio, S.; Russo, A.; Ezsol, Z.; Tonutti, L.; Taboga, C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulindependent diabetic subjects. Eur. J. Clin. Invest 28:329-333; 1998.
47. Ceriello, A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet. Med. 15:188-193; 1998.
48. Lee, I. K.; Kim, H. S.; Bae, J. H. Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia. Int. J. Clin. Pract. Suppl 59-64; 2002.
49. Schinkovitz, A.; Dittrich, P.; Wascher, T. C. Effects of a high-fat meal on resistance vessel reactivity and on indicators of oxidative stress in healthy volunteers. Clin. Physiol 21:404-410; 2001.
50. Li, J. M.; Shah, A. M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J Physiol Regul. Integr. Comp Physiol 287:R1014-R1030; 2004.
51. Mueller, C. F.; Widder, J. D.; McNally, J. S.; McCann, L.; Jones, D. P.; Harrison, D. G. The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circ. Res 97:637-644; 2005.
52. Pagano, P. J.; Ito, Y.; Tornheim, K.; Gallop, P. M.; Tauber, A. I.; Cohen, R. A. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am. J Physiol 268:H2274-H2280; 1995.
53. Droge, W. Free radicals in the physiological control of cell function. Physiol Rev. 82:47-95; 2002.
54. Cadenas, E.; Davies, K. J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med 29:222-230; 2000.
55. Finkel, T. Opinion: Radical medicine: treating ageing to cure disease. Nat. Rev. Mol. Cell Biol. 6:971-976; 2005.
56. Raha, S.; Robinson, B. H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25:502-508; 2000.
57. Venugopal, J.; Hanashiro, K.; Yang, Z. Z.; Nagamine, Y. Identification and modulation of a caveolaedependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes. Proc. Natl. Acad. Sci. U. S. A 101:17120-17125; 2004.
58. Roberts, C. K.; Barnard, R. J.; Sindhu, R. K.; Jurczak, M.; Ehdaie, A.; Vaziri, N. D. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 55:928-934; 2006.
59. Bellin, C.; de Wiza, D. H.; Wiernsperger, N. F.; Rosen, P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res 38:732-739; 2006.
60. Goldstein, B. J.; Mahadev, K.; Wu, X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54:311-321; 2005.
61. Avogaro, A.; de Kreutzenberg, S. V.; Fadini, G. P. Oxidative stress and vascular disease in diabetes: is the dichotomization of insulin signaling still valid? Free Radic. Biol. Med. 44:1209-1215; 2008.
62. McClung, J. P.; Roneker, C. A.; Mu, W.; Lisk, D. J.; Langlais, P.; Liu, F.; Lei, X. G. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc. Natl. Acad. Sci. U. S. A 101:8852-8857; 2004.
63. McGarry, J. D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18; 2002.
64. Boden, G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10; 1997.
65. Hotamisligil, G. S.; Peraldi, P.; Budavari, A.; Ellis, R.; White, M. F.; Spiegelman, B. M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668; 1996.
66. Cohen, B.; Novick, D.; Rubinstein, M. Modulation of insulin activities by leptin. Science 274:1185-1188; 1996.
67. Randle, P. J.; Kerbey, A. L.; Espinal, J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev. 4:623-638; 1988.
68. Steppan, C. M.; Bailey, S. T.; Bhat, S.; Brown, E. J.; Banerjee, R. R.; Wright, C. M.; Patel, H. R.; Ahima, R. S.; Lazar, M. A. The hormone resistin links obesity to diabetes. Nature 409:307-312; 2001.
69. Steinberg, H. O.; Chaker, H.; Leaming, R.; Johnson, A.; Brechtel, G.; Baron, A. D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest 97:2601-2610; 1996.
70. Laakso, M.; Edelman, S. V.; Brechtel, G.; Baron, A. D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest 85:1844-1852; 1990.
71. Ritz, P.; Berrut, G. Mitochondrial function, energy expenditure, aging and insulin resistance. Diabetes Metab 31 Spec No 2:5S67-5S73; 2005.
72. Frisard, M.; Ravussin, E. Energy metabolism and oxidative stress: impact on the metabolic syndrome and the aging process. Endocrine. 29:27-32; 2006.
73. Petersen, K. F.; Befroy, D.; Dufour, S.; Dziura, J.; Ariyan, C.; Rothman, D. L.; DiPietro, L.; Cline, G. W.; Shulman, G. I. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140-1142; 2003.
74. Inoguchi, T.; Sonta, T.; Tsubouchi, H.; Etoh, T.; Kakimoto, M.; Sonoda, N.; Sato, N.; Sekiguchi, N.; Kobayashi, K.; Sumimoto, H.; Utsumi, H.; Nawata, H. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc. Nephrol. 14:S227-S232; 2003.
75. Brownlee, M. A radical explanation for glucose-induced beta cell dysfunction. J. Clin. Invest 112:1788-1790; 2003.
76. Kim, J. A.; Wei, Y.; Sowers, J. R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res 102:401-414; 2008.
77. Crimi, E.; Ignarro, L. J.; Napoli, C. Microcirculation and oxidative stress. Free Radic. Res 41:1364-1375; 2007.
78. Wiernsperger, N.; Nivoit, P.; De Aguiar, L. G.; Bouskela, E. Microcirculation and the metabolic syndrome. Microcirculation. 14:403-438; 2007.
79. Wang, Y.; Marsden, P. A. Nitric oxide synthases: biochemical and molecular regulation. Curr. Opin. Nephrol. Hypertens. 4:12-22; 1995.
80. Cooke, J. P.; Dzau, V. J. Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med. 48:489-509; 1997.
81. Ignarro, L. Activation and regulation of the nitric oxide-cGMP pathway by oxidative stress. In Forman, H.; Cadenas, E. eds. Oxidative stress and signal transduction. New York: Chapmann & Hall; 1997:32-51.
82. Archer, S. L.; Huang, J. M.; Hampl, V.; Nelson, D. P.; Shultz, P. J.; Weir, E. K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A 91:7583-7587; 1994.
83. Robertson, B. E.; Schubert, R.; Hescheler, J.; Nelson, M. T. cGMP-dependent protein kinase activates Caactivated K channels in cerebral artery smooth muscle cells. Am. J. Physiol 265:C299-C303; 1993.
84. Spear, N.; Estévez, A.; Radi, R.; Beckmann, J. Activation and regulation of the nitric oxide-cyclich GMP signal transduction pathway by oxidative stress. In Forman, H.; Cadenas, E. eds. Oxidative stress and signal transduction. New York: Chapmann & Hall; 1997:3-31.
85. Ohara, Y.; Peterson, T. E.; Harrison, D. G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin. Invest 91:2546-2551; 1993.
86. Bouloumie, A.; Bauersachs, J.; Linz, W.; Scholkens, B. A.; Wiemer, G.; Fleming, I.; Busse, R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 30:934-941; 1997.
87. Zou, M. H.; Shi, C.; Cohen, R. A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin. Invest 109:817-826; 2002.
88. Schmidt, T. S.; Alp, N. J. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin. Sci. (Lond) 113:47-63; 2007.
89. Cai, S.; Khoo, J.; Mussa, S.; Alp, N. J.; Channon, K. M. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48:1933-1940; 2005.
90. Frisbee, J. C.; Delp, M. D. Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem. 42:145-161; 2006.
91. Dell'Omo, G.; Penno, G.; Pucci, L.; Mariani, M.; Del Prato, S.; Pedrinelli, R. Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis 172:383-389; 2004.
92. Sun, Y. X.; Hu, S. J.; Zhang, X. H.; Sun, J.; Zhu, C. H.; Zhang, Z. J. [Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders]. Zhejiang. Da. Xue. Xue. Bao. Yi. Xue. Ban. 35:315-318; 2006.
93. Hsueh, W. A.; Quinones, M. J. Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol. 92:10J- 17J; 2003.
94. Laakso, M.; Sarlund, H.; Mykkanen, L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223-231; 1990.
95. Murdie, P. Link between insulin resistance, ethnicity and endothelial dysfunction. Nat Clin Pract Cardiovasc Med 2, 498. 2005.
96. Anastasiou, E.; Lekakis, J. P.; Alevizaki, M.; Papamichael, C. M.; Megas, J.; Souvatzoglou, A.; Stamatelopoulos, S. F. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 21:2111-2115; 1998.
97. Tooke, J. E.; Goh, K. L. Endotheliopathy precedes type 2 diabetes. Diabetes Care 21:2047-2049; 1998.
98. Balletshofer, B. M.; Rittig, K.; Enderle, M. D.; Volk, A.; Maerker, E.; Jacob, S.; Matthaei, S.; Rett, K.; Haring, H. U. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780-1784; 2000.
99. Caballero, A. E. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch. Med Res 36:241-249; 2005.
100. Caballero, A. E. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr. Diab. Rep. 4:237-246; 2004.
101. Caballero, A. E.; Arora, S.; Saouaf, R.; Lim, S. C.; Smakowski, P.; Park, J. Y.; King, G. L.; LoGerfo, F. W.; Horton, E. S.; Veves, A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48:1856-1862; 1999.
102. Freeman, D. J.; Norrie, J.; Caslake, M. J.; Gaw, A.; Ford, I.; Lowe, G. D.; O'Reilly, D. S.; Packard, C. J.; Sattar, N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600; 2002.
103. Festa, A.; D'Agostino, R., Jr.; Tracy, R. P.; Haffner, S. M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137; 2002.
104. Enderle, M. D.; Benda, N.; Schmuelling, R. M.; Haering, H. U.; Pfohl, M. Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects. Diabetes Care 21:271-277; 1998.
105. Houben, A. J.; Schaper, N. C.; de Haan, C. H.; Huvers, F. C.; Slaaf, D. W.; de Leeuw, P. W.; Nieuwenhuijzen Kruseman, A. C. The effects of 7-hour local hyperglycaemia on forearm macro and microcirculatory blood flow and vascular reactivity in healthy man. Diabetologia 37:750-756; 1994.
106. Clarkson, P.; Celermajer, D. S.; Donald, A. E.; Sampson, M.; Sorensen, K. E.; Adams, M.; Yue, D. K.; Betteridge, D. J.; Deanfield, J. E. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 28:573-579; 1996.
107. Arcaro, G.; Zenere, B. M.; Saggiani, F.; Zenti, M. G.; Monauni, T.; Lechi, A.; Muggeo, M.; Bonadonna, R. C. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care 22:1536-1542; 1999.
108. Schalkwijk, C. G.; Stehouwer, C. D. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin. Sci. (Lond) 109:143-159; 2005.
109. Clark, M. G.; Wallis, M. G.; Barrett, E. J.; Vincent, M. A.; Richards, S. M.; Clerk, L. H.; Rattigan, S. Blood flow and muscle metabolism: a focus on insulin action. Am. J Physiol Endocrinol. Metab 284:E241-E258; 2003.
110. Assumpcao, C.; Brunini, T.; Matsuura, C.; Resende, A.; Mendes-Ribeiro, A. Impact of the L-arginine-nitric oxide pathway and oxidative stress on the pathogenesis ogf the metabolic syndrome. The Open Biochem J 2:108-115; 2008.
111. Zeng, G.; Nystrom, F. H.; Ravichandran, L. V.; Cong, L. N.; Kirby, M.; Mostowski, H.; Quon, M. J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101:1539-1545; 2000.
112. He, Z.; Opland, D. M.; Way, K. J.; Ueki, K.; Bodyak, N.; Kang, P. M.; Izumo, S.; Kulkarni, R. N.; Wang, B.; Liao, R.; Kahn, C. R.; King, G. L. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler. Thromb. Vasc. Biol. 26:787-793; 2006.
113. Forman, H. J.; Cadenas, E. Oxidative stress and signal transduction: New York Chapman & Hall; 1997.
114. Schulze-Osthoff, K.; Bauer, M.; Wesselborg, S.; Baeuerle, P. Reactive oxygen species as primary signals and second messenger in the activation of transcription factors. In Forman, H.; Cadenas, E. eds. Oxidative stress and signal transduction. New York: Chapmann & Hall; 1997:239-259.
115. Simon, A.; Fanburg, B.; Cochran, B. STAT activation by oxidative stress. In Forman, H.; Cadenas, E. eds. Oxidative stress and signal transduction. New York: Chapmann & Hall; 1997:260-271.
116. Lenardo, M. J.; Baltimore, D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58:227-229; 1989.
117. Xie, Q. W.; Kashiwabara, Y.; Nathan, C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol. Chem. 269:4705-4708; 1994.
118. He, Z.; King, G. L. Microvascular complications of diabetes. Endocrinol. Metab Clin North Am. 33:215-xii; 2004.
119. King, G. L.; Ishii, H.; Koya, D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int. Suppl 60:S77-S85; 1997.